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Bladder cancer is the most common malignancy of the urinary tract, having one of
the highest recurrence rates and progression from non-muscle to muscle invasive
bladder cancer that commonly leads to metastasis. Cystoscopy and urine cytology
are the standard procedures for its detection but have limited clinical sensitivity and
specificity. Herein, a microfluidic device, the UriChip, was developed for the enrichment
of urothelial exfoliated cells from fresh and frozen urine, based on deformability and
size, and the cancer-associated glycan Sialyl-Tn explored as a putative bladder cancer
urinary biomarker. Spiking experiments with bladder cancer cell lines showed an isolation
efficiency of 53%, while clinical sample analyses revealed retention of cells with various
morphologies and sizes. in situ immunoassays demonstrated significantly higher number
of Sialyl-Tn-positive cells in fresh and frozen voided urine from bladder cancer patients,
compared to healthy individuals. Of note, urothelial exfoliated cells from cryopreserved
urine sediments were also successfully isolated by the UriChip, and found to express
significantly high levels of Sialyl-Tn. Remarkably, Sialyl-Tn expression is correlated with
tumor stage and grade. Overall, our findings demonstrate the potential of UriChip
and Sialyl-Tn to detect urothelial bladder cancer cells in follow-up and long-term
retrospective studies.
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INTRODUCTION
Bladder cancer (BC) is the most common malignancy of the
urinary tract (1). Cystoscopy and urine cytology are the standard
pathological procedures for its detection (2, 3). However,
cystoscopy is an invasive and expensive method with limited
and operator-dependent sensitivity (4). On the other hand, urine
cytology has low sensitivity for low-grade papillary tumors,
depends on the examiner’s subjective opinion, and displays long
turnaround times (5–7). Although most patients are diagnosed
with non-muscle invasive BC (NMIBC), which has a 5-year
survival rate of 90% (8, 9), high recurrence rates (30–80%)
impose long-term cystoscopy and cytology-based follow-ups
after transurethral resection of malignant lesions (10, 11). Thus,
management of BC is a hurdle with extremely high costs to
health care systems (12, 13). To circumvent this issue, distinct
BC biomarker assays have been developed targeting tumor-
derived proteins or genetic material in voided urine (14–16).
A few have reached commercialization, like the Urovysion and
Immunocyt kits, showing superior sensitivity when compared
to cytology (17). Still, their implementation in clinical diagnosis
has been hampered by their high false-positive rates, complexity
and high cost (18). In turn, BTA stat and BTA trak tests, which
detect urinary human complement factor H-related protein,
and NMP22/BladderChek, another protein-based test, have
shown to report with limited sensitivity and selectivity for the
diagnosis of BC (19–21). Hence, novel platforms and urinary
biomarkers that may assist in early detection and monitoring
of BC, as a non-invasive and cost-effective strategy, are of
outmost importance.
Due to their high throughput and low cost, microfluidic-
based diagnostic tools hold the promise for improved patient care
and outcomes considering the limitations of current screening
and diagnostic techniques as well as the societal and economic
impact of BC (22, 23).Microfluidics enables precisemanipulation
of biological samples and can potentially provide portability
and automation, offering exceptional advantages for clinical
application (24). A panoply of microfluidic chips have been
developed for blood-based biopsies, i.e., isolation of circulating
tumor cells (CTCs) and/or tumor-derived material from blood of
cancer patients with outstanding results (25–27). In the context
of BC, we have recently reported two distinct microfluidic
devices for CTC isolation and analysis (28, 29), while Alva
et al. evaluated CTCs captured by the commercial system
Isoflux (30). Despite the prognostic significance of CTCs in BC,
microfluidic analysis of putative cancer biomarkers in voided
urine would be ideal, non-invasive and provide significant
benefits for patient monitoring, particularly at early stages of
the disease, when survival rates are higher and CTCs may not
yet be present. Nevertheless, only a scarcity of studies have
used microfluidic chips for urine-based BC detection, employing
different detection principles, complex systems, and processing
times (31–34).
Built on our previous work regarding the development of
microfluidic platforms for the capture of BC CTCs (28, 29),
we herein report a new microfluidic chip for exfoliated tumor
cell (ETC) enrichment from voided urine of BC patients.
Importantly, ETCs are valuable sources of information regarding
tumor biology and dynamics throughout the course of BC and
treatment-follow up (35). A schematic representation of the
experimental design used in this study is shown in Figure 1.
This label-free strategy, based on cell size and deformability,
allowed unbiased retention of ETCs of various sizes and
morphologies. Moreover, ETCs were successfully isolated from
fresh voided urine samples as well as from cryopreserved
urine sediments, which to the best of our knowledge had
never been assessed, revealing the feasibility of the system for
retrospective analyses. A double marker analysis was performed
using pan-cytokeratin (pan-CK) and Sialyl-Tn (STn), a tumor
associated antigen overexpressed in BC but absent in the healthy
urothelium (36). Our experiments showed, for the first time,
STn expression in ETCs from patients, which correlated with
staging and grading of BC. Noteworthy, data resulted from
two independent data sets, corroborating the versatility of this
platform and the potential of STn as a novel biomarker in
liquid biopsies.
MATERIALS AND METHODS
Design and Fabrication of the UriChip
Microfluidic Device
Masters were designed in AutoCAD software (Autodesk, USA)
and consist of five rows of posts with increasingly narrower gap
widths (50, 20, 15, 10, and 5µm) (Figures 2A,B), allowing for a
wide size-range of urothelial exfoliated cells to be captured (37,
38). A set of square posts with 100µm gaps were incorporated
for structural support of the channels and to prevent the device
from clogging with urinary debris and large cell clusters. The
design was patterned by direct write laser lithography (DWL
2.0 Heidelberg, Germany) on 200mm silicon wafers (P/Boron,
<100>, Siegert Wafer, Germany). Features with 20µm depth
were defined by silicon deep reactive ion etching (DRIE,
STPS Pegasus, United Kingdom) with sulfur hexafluoride (SF6,
Sigma 366 Aldrich, USA), and exposed areas passivated with
octafluorocyclobutane (C4F8, Sigma Aldrich, USA). The etching
of the features was confirmed by SEM inspection. Photoresist
residues were stripped by oxygen plasma (PVA Tepla GIGAbatch
360M, Germany) and the wafer was diced using a DAD 3350
Dicing Saw (Disco, Japan). Masters were then cleaned with
isopropyl alcohol (IPA, Sigma- Aldrich, USA), rinsed with
deionized water and dried at 150◦C. Finally, masters were
hydrophobized through treatment with trichloro(1H,1H,2H,2H-
perfluorooctyl)silane (97%, Sigma-Aldrich, USA) and cured for
1 h at 65◦C.
Devices were fabricated in polydimethylsiloxane (PDMS,
Ellsworth Adhesives Iberica, Spain), which was prepared as
a two-part system with mix ratio of 10:1 (w/w) base/curing
agent, poured over the master, degassed and cured for 2 h
at 65◦C. Following that, the PDMS was unmolded and inlet
and outlet made using a puncher. Irreversible bonding was
achieved through surface activation of clean glass slides and
PDMS replicas by low power oxygen plasma for 15 s (PDC-002-
CE, Harrick Plasma, USA). Immediately after fabrication and
bonding (Figure 2C1), microfluidic devices were connected to a
multi-channel pressure controller which allows the simultaneous
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FIGURE 1 | Schematic representation of the enrichment and analysis of urothelial exfoliated cells from bladder washes and voided urine of BC patients using the
UriChip. Bladder washes and voided urine from BC patients were collected, subjected or not to cryopreservation and run into the UriChip. A dual biomarker
immunoassay was then performed, comprising pan-CK (epithelial marker), STn (tumor associated marker), and DAPI (nuclei staining). Trapped cells were next imaged
by immunofluorescence microscopy and nucleated cells expressing STn and/or CK counted. In parallel, corresponding FFPE tissues were screened for STn by
immunohistochemistry and results compared to clinicopathological information of patients.
run of up to four independent devices (MFCSTM-EZ, Fluigent,
France) (Figure 2C2), and channels firstly primed with ethanol
70% (v/v) at 100 mbar to enhance the wettability, then rinsed
with 10mM of Phosphate Buffered Saline (PBS, Sigma-Aldrich,
USA) at 200 mbar and lastly treated with 1% (w/v) Pluronic F-
127 (Sigma-Aldrich, USA) overnight at 4◦C to avoid unspecific
cell attachment.
Cell Culture
Human urinary BC cell lines HT1376 and MCR-STn
[overexpressing the sialyl-Tn antigen (39)] were grown in
monolayer culture and maintained at 37◦C in an atmosphere
of 5% CO2 in RPMI 1640 GlutaMAX (Invitrogen, USA) and
DMEM high glucose (Invitrogen, USA), respectively. Media
were supplemented with 10% heat-inactivated fetal bovine
serum and 1% penicillin-streptomycin (both from Invitrogen,
USA). Cells were continuously monitored by microscopy to
ensure they maintained their original morphology. Where
appropriate, BC cells were harvested by incubation in 0.25%
Trypsin-EDTA (Invitrogen, USA), washed with PBS and labeled
with 12.5µM calcein-AM (Sigma Aldrich, USA) according to
the manufacturer’s instructions.
Isolation of Human PBMCs
Peripheral blood (3mL) was collected from healthy blood
donors after informed consent, layered over histopaque-
1077 (Sigma-Aldrich, USA) and centrifuged at room
temperature for 10min at 650 g, without active break.
Peripheral blood mononuclear cells (PBMCs) were then
gently collected from the gradient interface, washed twice
and resuspended in PBS supplemented with 2% bovine
serum albumin (BSA, Sigma-Aldrich, USA). Cell viability
and concentration were determined using the Tuerk solution
(Sigma-Aldrich, USA).
Collection and Processing of Patient
Samples
BC patients were enrolled at the Urology department of Hospital
da Senhora daOliveira, Guimarães, Portugal (n= 8) andHospital
Universitario 12 de Ocubre, Madrid, Spain (n = 6). Voided
urine samples (30–50mL) from 14 patients were collected prior
to transurethral resection of bladder tumor (TURBT). Bladder
wash samples (10–30mL) were obtained after flushing the
bladder with saline buffer immediately before TURBT. Table 1
summarizes clinicopathological information obtained from the
patients’ clinical records. Biological samples were processed
within 3 h upon collection, being centrifuged at 1,200 rpm for
5min and washed twice in PBS. Pellets were then resuspended
in 500 µL of PBS-2%BSA for immediate microfluidic analysis or
frozen at −80◦C for later analysis. As a normal control group,
voided urine samples (n= 6) from healthy subjects were obtained
and subjected to the same protocol. Formalin-fixed paraffin-
embedded (FFPE) tumor tissue sections were also included in
the study. All procedures were performed after patient informed
consent and approval by the Ethics Committee of both hospitals.
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FIGURE 2 | Design and fabrication of the UriChip. (A) AutoCAD design of the UriChip. Design includes a circular inlet and outlet, square posts for structural support of
the channels, pre-filtering system to prevent debris and large cell clusters, and five row of posts with increasingly narrower gap widths (50, 20, 15, 10, and 5µm) to
separate cells according to their size and deformability. (B) Scanning electron microscopy (SEM) image of the five rows of gaps in the master that will give rise to the
posts of the UriChip. Scale bar, 100µm. (C1) UriChip after fabrication with PDMS. (C2) Experimental setup for simultaneous analysis of four independent samples.
Analysis of Cell Entrapment in the UriChip
Devices
HT1376 cells (1,000 cells in 500 µL of PBS) previously labeled
with calcein-AM were injected into the UriChip microfluidic
devices at two different inlet pressures (200 and 300 mbar) with
the help of a pressure pump. Trapped cells were then fixed with
4% (w/v) formaldehyde solution (Sigma-Aldrich, USA) during
20min and finally washed with PBS. Capture efficiency (CE)
of HT1376 cells was determined by imaging and counting the
number of calcein-AM-positive cells captured and comparing
with the total input.
CE (%) = (captured HT1376 cells)/(total input HT1376 cells)
× 100
To determine cancer cell capture purity in the presence of
leucocytes (which may be found in the urine due to cancer
associated inflammation), calcein-AM-stainedHT1376 cells were
next spiked in 500 µL of PBS containing unlabeled PBMCs at a
1:10 ratio, run at 200mbar and fixed with 4% (w/v) formaldehyde
solution as described above. Cell purity and PBMC retention
were determined according the following formulas:
Purity (%) = [(captured HT1376 cells)/(captured HT1376
cells+ captured PBMCs)]× 100
PBMC retention (%) = (captured PBMCs)/(total input
PBMCs)× 100
Similarly, to evaluate the efficiency of isolating cancer cells from
voided urine, MCR-STn cells were pre-stained with calcein-AM
for 30min at 37◦C, spiked in 500 µL of PBS-2%BSA containing
urine sediment from healthy subjects and run at 200 mbar. Cells
were then fixed with 4% (w/v) formaldehyde solution and finally
washed with PBS. The number of calcein-AM-positive MCR-STn
cells captured in the device was compared to the total number of
MCR-STn cells spiked, and CE determined.
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TABLE 1 | Clinicopathological features of patients included in this study.






Low grade 11 (78.57%)
High grade 3 (21.43%)
NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; BC,
bladder cancer.
Immunofluorescence Cell Staining and
Detection
Patient samples (processed bladder washes or voided urine)
were resuspended in PBS-2%BSA and injected into the chips
at 200 mbar. After a 30min incubation period with no
flow to reduce unspecific binding, cells were fixed with 4%
(w/v) formaldehyde for 20min and further treated with 0.25%
Triton X-100 in PBS for 5min to induce cellular permeability.
Subsequently, two washes with PBS were performed and mouse
monoclonal anti-CK pan-FITC antibody (1:100 Clone C-11)
and DAPI (1:1,000, both from Sigma-Aldrich, USA) diluted
in PBS-2%BSA were loaded into the UriChips for 1 h in the
dark. The immunostaining process ended by washing with
PBS before imaging, with the flow rate set at 200 mbar
during the entire procedure. Where appropriate, cells were also
immunostained using the anti-STn mouse monoclonal antibody
clone B72.3 (0.25µg/mL in PBS-2%BSA, Abcam, UK) for 1 h
and 30min at room temperature, and labeled with a secondary
goat anti-mouse IgG-TRITC antibody (1:1,000 in PBS-2%BSA,
ThermoFisher Scientific, USA) for one additional hour, prior to
cell fixation and permeabilization. Following sample processing,
a fluorescence microscopy analysis of the captured cells was
performed under an inverted fluorescence microscope (Ti-E,
Nikon, Spain). A total of twenty-five fields (20x) per device were
selected randomly and the number of captured cells counted.
Only DAPI and STn-positive cells with identifiable cellular
morphology and well-delimited cytoplasm were considered for
cell enumeration, and count normalized to the total number of
DAPI-positive cells.
Tissue Immunohistochemistry
FFPE tissue sections from patients with BCwere screened for STn
staining using the streptavidin/biotin peroxidase method with
the anti-STn antibody, as previously described (29).
Neuraminidase Treatment
Samples were incubated with Clostridium perfringens
neuraminidase (0.1 unit/mL, Sigma-Aldrich, USA) for
2 h at 37◦C to cleave terminal sialic acid residues from
glycoproteins on cell surfaces. The reaction was stopped with
PBS washes.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism, version
5 (GrapPad Software, Inc., La Jola, CA, USA). Data is presented
as mean ± SD. Deviation from normality was tested using the
D’Agostino and Pearson normality test. The Mann-Whitney test
was used for unpaired samples and differences were considered to
be significant when p< 0.05 (∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001).
RESULTS
UriChip Performance With BC Cell Lines
The performance of the microfluidic device to capture BC cells
was firstly investigated using HT1376 BC cells as a model, pre-
stained with calcein-AM and spiked in PBS. As illustrated in
Figure 3A, cells captured inside the chip were morphologically
intact and remained mostly trapped in the rows of posts with
15–10µm spacing, in agreement with their average cell size
(15.5µm, Figure S1A), and their higher ability to deform as
compared to non-malignant counterparts (40).
To avoid the risk of device leaking and ensure the proper
and intact morphology of urothelial exfoliated cells during the
microfluidic capture, 300 mbar of inlet pressure was applied
in the UriChip. On the other hand, to prevent squeezing of
urothelial cells through the microposts under pressure and
consequently their loss to the outlet, the minimum inlet pressure
of 200 mbar was tested. By working on the range of 200–300
mbar, results revealed a higher CE of HT1376 cells at 200 mbar
when compared to 300 mbar input pressure (Figure 3B). This
result can be explained by increased hydrodynamic forces acting
on the post-trapped cells at higher pressure values, causing cell
loss. Hence, in all subsequent experiments the inlet pressure was
set to 200 mbar.
Given that the urine of BC patients is heterogeneous
and usually contains leucocytes due to cancer associated
inflammation, we next investigated the CE of HT1376 cells
pre-stained with calcein-AM in the presence of non-labeled
PBMCs isolated from healthy donors, spiked in PBS. PBMC
population comprises lymphocytes and monocytes that range
between 7 and 15µm in diameter with a high deformability
capacity (41). Notably, CE of HT1376 cells increased up to
50% in comparison to single cell population suspensions, while
PBMC retention was minimal (Figure 3C). In fact, a PBMC
depletion of 96.1% was observed, hence maintaining high sample
purity (62%).
Capture and Analysis of Human Urothelial
Exfoliated Cells in the UriChip
Having confirmed the ability of the UriChip to isolate BC cells
in single and mixed model samples, we further evaluated its
potential for the capture and analysis of cells from clinical
samples, known to be much more complex and heterogeneous.
As such, we analyzed both bladder wash samples, which
are highly cellular and contain well-preserved cells (42), as
well as voided urine from BC patients and compared them
to voided urine from healthy subjects. As expected, several
types of urothelial exfoliated cells with distinct morphological
features were observed either in healthy controls and patient
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FIGURE 3 | UriChip performance with HT1376 bladder cancer cells. (A) HT1376 cells (pre-stained with calcein-AM) captured in the UriChip and visualized by
fluorescence microscopy. Scale bar, 20µm. (B) Capture efficiency (CE) of HT1376 cancer cells spiked in PBS and run at 200 and 300 mbar. (C) CE of HT1376 cells
spiked in PBS solution containing PBMCs at 200 mbar input pressure (50%). Results are described as Mean ± S.D. of three independent experiments. * indicates
statistical significance (p < 0.05).
samples (Figure 4A). Indeed, the urothelium is composed of
multiple epithelial cell layers, namely basal, intermediate and
umbrella cells (43, 44). Basal cells, which localize on the
basal membrane of the bladder lining, are smaller (∼10µm
in diameter), mononucleated, and cuboidal-rounded shape
(Figure 4A1). Intermediate cells are pyriform in shape, 10–
25µm in diameter, and constitute the majority of the urothelium
(Figure 4A2). Umbrella cells, the most superficial cells of the
bladder lining, display a very large cytoplasm (25–250µm
in diameter), large and rounded nucleus sometimes bi- or
multinucleated, as well as prominent nucleoli (Figure 4A3)
(45). In addition, in patient samples, we also identified cells
with increased nuclear/cytoplasmic (N/C) ratio, irregular nuclear
borders and irregular chromatin patterns. Cells were found
either isolated or in clusters, exhibiting various shapes and sizes,
including CMV-like atypical cells with an “eye-bird” appearance
(Figure 4A4); cells with enlarged nucleus or multinucleated
(Figures 4A5,6), clusters of atypical cells (Figure 4A7), spindle-
like cells (Figure 4A8), and granular membrane atypical cells
(Figure 4A9), as previously reported (46–48). We further
evaluated the shape deformation of captured urothelial exfoliated
cells as they squeeze through the posts of the UriChip. Large
captured cells from healthy controls mostly localized within
upper rows of posts (≥20 gap width), while similar sized cells
from BC patients were able to deform more and squeeze through
narrower posts (Figure 4A10). These observations are supported
by the fact that malignant urothelial cells from voided urine
present reduced cell stiffness as compared to their healthy
counterparts (47).
Cytokeratins are highly expressed in intermediate filaments
of normal and neoplastic epithelial cells (49). Hence, to validate
the epithelial profile of captured cells from both healthy controls
and BC patients, an on-chip immunoassay was performed using a
pan-CK-FITC antibody. As illustrated in Figure 4B, the majority
of the cells trapped inside the microfluidic device were nucleated
and positive for cytokeratin expression, particularly in samples
from healthy donors.
These results highlight the potential of the UriChip to retain
cells of different sizes and shapes from voided urine, using a label-
free approach. Moreover, morphological analysis of captured
cells can be performed, and phenotypic characteristics identified
via in situ immunofluorescence.
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FIGURE 4 | Analysis of UriChip-captured urothelial exfoliated cells from biological samples. (A) Microscopy images showing different types of urothelial exfoliated cells
from human voided urine and bladder washes retained along the UriChip and stained for the nuclear marker DAPI (blue): (A1) basal cell, (A2) intermediate cells, (A3)
umbrella cells, (A4) CMV-like cell, (A5) cell with a large nucleus, (A6) multinucleated cells, (A7) cell clusters, (A8) spindle-shaped cells, (A9) membrane garrulous cells,
(A10) cell deformability capacity. (B) Isolated cells trapped between pillars of the UriChip were stained in situ with the anti-pan cytokeratin-FITC antibody (green) and
the nuclear marker DAPI (blue). Scale bar, 20µm.
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FIGURE 5 | MCR-STn bladder cancer cells captured in the UriChip. (A) Immunofluorescence analysis showing the pattern of STn (orange) and pan-CK (green)
expression in UriChip-captured MCR-STn cells. STn is mostly expressed at the cell membrane and cytoplasm of cancer cells. Cell nuclei were stained with DAPI
(blue). Scale bar, 25µm. (B) MCR-STn cells pre-labeled with calcein-AM (green) spiked in urine from healthy controls. Cell nuclei were stained with DAPI (blue). A
capture efficiency of 53% was achieved. Scale bar, 15µm.
Rigorous Identification of Urothelial ETCs
in Clinical Samples
In order to accurately identify urothelial ETCs and distinguish
them from benign ones, we selected STn, a tumor associated
antigen overexpressed in BC but absent in the healthy
urothelium, as malignant biomarker (36). Indeed, STn has
been directly associated with BC progression, metastatic
potential of neoplastic cells, and decreased overall survival
(28, 36). More importantly, we recently reported STn
expression in microfluidic-isolated CTCs from BC patients
(28, 29). For optimization purposes, we firstly used the
invasive BC cell line MCR overexpressing STn antigen (MCR-
STn), since STn levels in various non-transduced BC cells
lines, including HT1376, are negligible (data not shown)
(36). Figure 5A shows morphologically intact MCR-STn
cells retained within UriChip and expressing high levels of
STn mostly at the cell membrane but also intracellularly.
Neuraminidase treatment confirmed STn labeling specificity,
since after enzymatic release of STn no signal could be
detected in captured cells (Figure S2A). Furthermore, MCR-
STn cells were also immunostained for CK and found to be
positive, corroborating their epithelial nature and further
validating this dual marker microfluidic immunoassay
(Figure 5A).
STn expression enhances the migration and invasive capacity
of MCR cells (36), which are larger (average cell size of
20µm) than HT1376 (Figure S1B). In addition, cancer cells
become more deformable as they become more invasive. Hence,
considering that UriChip captures cells based on their size
and deformability, we next reassessed its performance, in even
more complex and heterogeneous samples such as urine. For
that purpose, MCR-STn cells were pre-labeled with calcein-AM,
spiked in voided urine from healthy donors, and stained for STn
antigen (Figure 5B). To perform an accurate quantification of
the BC cells trapped within the UriChip and rule out possible
variations of STn expression levels on MCR-STn cells, the
number of calcein and DAPI-positive cells was compared with
the total number of MCR-STn cells spiked. Remarkably, the CE
was found to be very similar (53%) to that achieved when using
HT1376 spiked in PBMCs, demonstrating the good consistency
of the UriChip for biological and heterogeneous samples.
STn Expression of Urothelial Exfoliated
Cells Correlates With Tumor Invasiveness
and Grade
We next moved to the pre-clinical testing of the UriChip
using both bladder washes and fresh voided urine from BC
patients and a combination of two biomarkers, STn and CK
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FIGURE 6 | STn expression in bladder urothelial ETC isolated by the UriChip. (A) Immunofluorescence staining pattern of urothelial exfoliated cells captured in the
UriChip from healthy controls and BC patient samples, namely bladder washes and voided urine, subjected or not to cryopreservation. Cells were probed for STn
antigen (orange), pan-CK (green), and DAPI (blue). ETCs were identified according to the following criteria: DAPI-positive, STn-positive, and pan-CK-positive or
negative. Scale bar, 20µm. (B) Percentage of STn and pan-CK-positive cells in BC patients vs. healthy controls. As expected, expression of STn is significantly higher
in BC (33.28%) compared with healthy controls (8.57%). p = 0.0006. In contrast, CK expression decreases significantly in BC (from 8.55% in healthy controls to
47.62% in BC). p = 0.0015. (C) Correlation of STn-positive and STn-positive/CK-negative cell count with tumor invasiveness and grade. Capture of STn-positive cells
and STn-positive/CK-negative cells in the UriChip are significantly higher in muscle invasive BC and high grade bladder tumors (p = 0.0127). Statistical significance
*p < 0.05, **p < 0.01, ***p < 0.001.
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to detect malignant cells. Of note, we extended this analysis
and evaluated UriChip and STn/CK immunoassay feasibility
to detect cells from cryopreserved samples, greatly relevant for
retrospective studies. Figure 6A depicts representative images
obtained for each condition tested and shows enhanced STn
expression in cells from BC patients as compared to healthy
controls. STn labeling was found to be specific as confirmed by
the loss of signal upon sample treatment with neuraminidase
(Figure S2B). Moreover, STn expression in corresponding tissue
sections was evaluated and found to be lower in low-grade
NMIBC in comparison to high-grade lesions (Figure S3), while
absent in the normal urothelium, in accordance with previous
reports (28, 36). CK-positive cells were also found in all samples
tested, characteristic of their epithelial origin. Remarkably, results
also demonstrated that it was possible to successfully entrap
urothelial cells subjected to cryopreservation, which retained
the morphologic features and the immunophenotypic markers
observed in non-preserved samples (Figure 6A). A quantitative
analysis of the captured cells from all fresh and cryopreserved
urine samples from BC patients was then performed, revealing
that patient urothelial exfoliated cells express significantly higher
levels of STn compared to healthy controls (Figure 6B). On the
other hand, a significant reduction in the number of CK-positive
cells from BC patients was detected (Figure 6B) suggesting a
distinct state of differentiation of these epithelial cells. More
importantly, we found significant correlations between STn
expression and tumor stage and grade, with STn-positive
cells decreasing CK expression with higher grade and stage
(Figure 6C).
DISCUSSION
The working principle of UriChip device is based on size-
exclusion and cell deformability, which allows for the capture
and characterization of urothelial ETCs. In fact, urothelial
ETCs, which are shed directly by the growing tumor in the
bladder, are known to reflect disease progression (24) and
for this reason, they have been widely used as a diagnostic
marker in urine cytology. However, the standard diagnostic
techniques, are limited considering the requirements for early-
cancer diagnosis (1, 50). UriChip has revealed to be a simple
and easy-to-use microfluidic device with easy fabrication and
cost-effective procedure having the potential to be produced
on an industrial scale and thus applied for clinical detection
in low-resource settings. Urothelial exfoliated cells of various
sizes and intact cellular morphology are efficiently harvested
by UriChip from large volumes of patient samples. In
addition, the design of five rows of posts with increasingly
narrower gap widths enables to handle a wide range of
urothelial exfoliated cells, both single and clustered, to be
captured and characterized by immunoassays. In addition,
the spatially square posts incorporated prevent the built-
up of cellular and non-cellular debris and the damage of
trapped cells.
Optimization tests were conducted with two distinct BC
cell models, prior to the analysis of clinical samples: bladder
washes, which contain well-preserved cells when collected before
TURBT (42), and voided urine from BC patients, both frequently
used for cytological assessment with equivalent results (51, 52).
Patient body fluids were then compared to voided urine from
healthy subjects. By using a multi-channel pressure controller,
which compensates the increase of flow resistance caused by the
numerous components of the urine, we were able to efficiently
process four independent samples in parallel without rupture or
leakage of the system. A few additional studies have also exploited
microfluidic chips for urinary cell-based BC detection. However,
these involved intricate equipment (31), long incubation periods
for surface functionalization and immune affinity selection (34)
or lacked clinical validation (32).
Spiking experiments demonstrated that, using the UriChip,
the CE of BC cells spiked in leukocytes and urine from healthy
donors achieved 53%, typical for size-based filtration (53, 54).
Higher efficiencies have recently been reported by Cheng et al.,
using a size-based microfluidic system, but with less complex
model samples, i.e., with BC cells diluted in PBS which do not
fully represent the cellular heterogeneity of biological samples
(33). Accordingly, cells with different sizes and morphologies
were found to be retained in the UriChip, with those originating
from BC patients exhibiting higher shape deformation capacity
and squeezing though narrower gaps in comparison to similar
sized urothelial cells from urine of healthy donors. Consistent
with our observations, previous reports using microfluidics and
other methodologies confirmed the reduced stiffness of bladder
and other cancerous cells compared to their non-malignant
counterparts (47, 55–57).
In addition, we phenotypically characterized captured cells
in situ, via a microfluidic immunoassay involving the epithelial
marker, pan-CK, and the tumor-associated glycan, STn. On-
chip immunostaining of CTCs isolated from blood samples
by microfluidics with distinct biomarkers has been extensively
performed (27, 58), and has also been tested with BC
urothelial exfoliated cells with good detection accuracy (33),
which demonstrates the potential of this approach for effective
screening and diagnosis of BC. Based on our previous work
showing that more than 90% of BC CTCs captured by a size-
based microfluidic device were STn positive (28, 29), we explored
the expression of STn in exfoliated cells present in voided urine.
Importantly, this antigen is overexpressed in primary bladder
tumors, lymph nodes, and distant metastasis, while absent or
marginally present on normal urothelium (28, 36), and correlates
with decreased overall survival (28). Moreover, STn has been
directly associated with a more aggressive phenotype of tumor
cells, conferring an invasive potential (59–61). Notably, we found,
for the first time, significant high levels of STn in captured
urothelial exfoliated cells from voided urine of BC patients. STn
expression in corresponding primary tumors was also evaluated
in all patients tested and found to be positive. Additionally,
STn expression in urinary BC cells significantly correlated with
tumor grade and invasiveness, in agreement with STn expression
pattern in the tissue, further supporting previously reported
findings (28, 29). Notably, a detailed analysis of the STn-positive
cell population revealed that these cells display lower levels of
CK, indicative of a more mesenchymal-like phenotype. This was
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particularly evident in more advanced grade tumors, supportive
of STn association with tumor aggressiveness. These results
suggest that throughout BC progression, urothelial cells undergo
an epithelial to mesenchymal transition, with increased potential
to invade. Accordingly, we have previously reported that the
percentage of CTCs expressing STn was three times higher than
those expressing the epithelial marker EpCAM (29), thus linking
STn to tumor progression and dissemination.
Parallel to the analysis of fresh clinical samples, we also
evaluated cryopreserved patient samples in the UriChip. Results
showed that cryopreserved BC cells were successfully isolated and
maintained the morphologic features and phenotypic markers,
evidencing the versatility of this low-cost system and its feasibility
for multi-centric and retrospective analysis on archived samples.
To the best of our knowledge, this is the first study evaluating
cryopreserved urine sediments by microfluidics. Yet, a large-
scale clinical trial is needed to validate the device, particularly
for clinical implementation. Proper external regulatory approval
would be also necessary. Increasing the cohort of patients with
BC (from different grades and stages) will enable to assess the
detection accuracy of UriChip. Additionally, further studies by
combining UriChip immunoassay with traditional cytology and
comparing with commercial available FDA-approved markers
are warranted to validate the present findings. Furthermore,
the capture and enrichment of intact urothelial exfoliated cells
within UriChip provide the opportunity for downstream on-chip
proteomic and off-chip single-cell genomic analyses for a precise
diagnosis of BC.
Overall, UriChip microfluidic-based platform is able to
efficiently capture and enrich urothelial exfoliated cells, from
both fresh and frozen voided urine of BC patients, according to
their size and deformability. Notably, STn expression in ETCs
from patients from two independent data sets was demonstrated
herein for the first time, which correlated with staging and
grading of BC.
Combination with high-throughput processing and
automation may constitute a first step toward a fully integrated
system for rapid label-free capture, on-chip phenotypic
characterization and enumeration of BC cells. In addition,
exploring glycosylation of tumor cells in body fluids, namely
STn expression, will offer a more selective malignant cell
isolation, paving the way to downstream molecular analysis and
fostering precision medicine applications in bladder cancer and
other malignancies.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
article/Supplementary Material.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by the ethics committee of Hospital Senhora
da Oliveira, Guimarães, Portugal. The patients/participants
provided their written informed consent to participate in
this study.
AUTHOR CONTRIBUTIONS
SC was responsible for the study design, patient samples
processing, analytical measurements in vitro, data analysis,
and manuscript writing. CA and LD were responsible for
the design and fabrication of the UriChip microfluidic
device and evaluation of its performance. DF performed
tissue immunohistochemistry experiments. RR, VG, and MD
selected and collected patient samples. LL, JF, LS, MM-F,
MD, CS-C, JP, and PF contributed to the interpretation of
the experimental data. MO was responsible for the project
conception, study design, data interpretation, and manuscript
writing. All authors discussed the results and commented on
the manuscript.
ACKNOWLEDGMENTS
The authors would like to thank the patients participating in this
study for providing samples and Professor Paula Videira (FCT-
UNL, Portugal) for kindly providing the MCR-STn cell model
used in this study. We wish to thank our funding source for this
research, the Cancer: Advancing Cancer Research: From Basic
Knowledge to Application (NORTE-01-0145-FEDER-000029),
supported by the Norte Regional Operational Programme
(NORTE2020), under the PORTUGAL 2020 Partnership
Agreement, through the European Regional Development Fund
(ERDF), partially by funds from Fondo Europeo de Desarrollo
Regional (FEDER), by grants from the Spanish Government
CB/16/00228, from Instituto de Salud Carlos III, and by funds
from Fundação para a Ciência e Tecnologia (FCT) (POCI-
01-0145-FEDER-031442-InNPeC, CEECIND/ 03186/2017
and PEst-OE/SAU/UI0776/201). FCT is co-financed by
European Social Fund (ESF) under Human Potential Operation
Programme (POPH) from National Strategic Reference
Framework (NSRF).
SUPPLEMENTARY MATERIAL




1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-
U, Choi W, et al. Bladder cancer. Lancet. (2016) 388:2796–810.
doi: 10.1016/S0140-6736(16)30512-8
2. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer
incidence and mortality: a global overview and recent trends. Eur Urol. (2017)
71:96–108. doi: 10.1016/j.eururo.2016.06.010
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C,
et al. GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide.
IARC Cancer Base No. 11. Lyon: International Agency for Research on
Cancer (2013).
4. Kołodziej A, Krajewski W, Matuszewski M, Tupikowski
K. Review of current optical diagnostic techniques for
non-muscle-invasive bladder cancer. Central Eur J Urol.
(2016) 69:150–6. doi: 10.5173/ceju.2016.780
Frontiers in Oncology | www.frontiersin.org 11 September 2020 | Volume 10 | Article 1774
Carvalho et al. UriChip for Detection of Bladder Cancer
5. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available
bladder tumor markers versus cytology: results of a comprehensive
literature review and meta-analyses. Urology. (2003) 61:109–18.
doi: 10.1016/S0090-4295(02)02136-2
6. Karakiewicz PI, Benayoun S, Zippe C, LÜDecke G, Boman H, Sanchez-
Carbayo M, et al. Institutional variability in the accuracy of urinary cytology
for predicting recurrence of transitional cell carcinoma of the bladder. BJU
Int. (2006) 97:997–1001. doi: 10.1111/j.1464-410X.2006.06036.x
7. Reid MD, Osunkoya AO, Siddiqui MT, Looney SW. Accuracy of grading
of urothelial carcinoma on urine cytology: an analysis of interobserver and
intraobserver agreement. Int J Clin Exp Pathol. (2012) 5:882–91.
8. Siddiqui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials
in non-muscle invasive bladder cancer. Urol Oncol. (2017) 35:516–27.
doi: 10.1016/j.urolonc.2017.06.043
9. Rayn KN, Hale GR, Grave GP-L, Agarwal PK. New therapies in
nonmuscle invasive bladder cancer treatment. Indian J Urol. (2018) 34:11–9.
doi: 10.4103/iju.IJU_296_17
10. Zieger K,Wolf H, Olsen PR, Højgaard K. Long-term follow-up of noninvasive
bladder tumours(stage Ta): recurrence and progression. BJU Int. (2000)
85:824–8. doi: 10.1046/j.1464-410x.2000.00547.x
11. Olivier Bosset P, Neuzillet Y, Paoletti X, Molinie V, Botto H, Lebret T. Long-
term follow-up of TaG1 non–muscle-invasive bladder cancer. Urol Oncol
Semin Orig Investig. (2015) 33:20.e21–7. doi: 10.1016/j.urolonc.2014.09.001
12. Sloan FA, Yashkin AP, Akushevich I, Inman BA. The cost to
medicare of bladder cancer care. Eur Urol Oncol. (2020) 3:515–22.
doi: 10.1016/j.euo.2019.01.015
13. Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The
economics of bladder cancer: costs and considerations of caring for this
disease. Eur Urol. (2014) 66:253–62. doi: 10.1016/j.eururo.2014.01.006
14. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine-based assays
for the detection of bladder cancer. Biomark Med. (2009) 3:265.
doi: 10.2217/bmm.09.23
15. Leiblich A. Recent developments in the search for urinary biomarkers in
bladder cancer. Curr Urol Rep. (2017) 18:100. doi: 10.1007/s11934-017-
0748-x
16. Tan WS, Tan WP, Tan M-Y, Khetrapal P, Dong L, deWinter P, et al. Novel
urinary biomarkers for the detection of bladder cancer: a systematic review.
Cancer Treat Rev. (2018) 69:39–52. doi: 10.1016/j.ctrv.2018.05.012
17. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers:
meta-analysis of diagnostic accuracy and comparison with urinary
cytology testing. Urol Oncol Semin Orig Investig. (2008) 26:646–51.
doi: 10.1016/j.urolonc.2007.06.002
18. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary
biomarkers for diagnosis of bladder cancer: a systematic review and meta-
analysisurinary biomarkers for diagnosis of bladder cancer. Ann Int Med.
(2015) 163:922–31. doi: 10.7326/M15-0997
19. Sarosdy MF, Hudson MLA, Ellis WJ, Soloway MS, White Rd, Sheinfeld J, et al.
Improved detection of recurrent bladder cancer using the bard bta stat test.
Urology. (1997) 50:349–53. doi: 10.1016/S0090-4295(97)00292-6
20. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BCS. Sensitivity and
specificity of NMP-22, telomerase, and BTA in the detection of human bladder
cancer. Urology. (1998) 52:398–402. doi: 10.1016/S0090-4295(98)00219-2
21. Malkowicz SB. The application of human complement factor H-related
protein (bta trak) in monitoring patients with bladder cancer.Urol Clin North
Am. (2000) 27:63–73. doi: 10.1016/S0094-0143(05)70235-4
22. Chiu DT, deMello AJ, Di Carlo D, Doyle PS, Hansen C, Maceiczyk RM,
et al. Small but perfectly formed? successes, challenges, and opportunities for
microfluidics in the chemical and biological sciences. Chem. (2017) 2:201–23.
doi: 10.1016/j.chempr.2017.01.009
23. Han SJ, Park H-K, Kim KS. Applications of microfluidic devices for urology.
Int Neurourol J. (2017) 21:S4–9. doi: 10.5213/inj.1734838.419
24. Streets AM, Huang Y. Chip in a lab: microfluidics for next generation life
science research. Biomicrofluidics. (2013) 7:011302. doi: 10.1063/1.4789751
25. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al.
Isolation of rare circulating tumour cells in cancer patients by microchip
technology. Nature. (2007) 450:1235–9. doi: 10.1038/nature06385
26. Kulasinghe A, Wu H, Punyadeera C, Warkiani ME. The use of microfluidic
technology for cancer applications and liquid biopsy. Micromachines. (2018)
9:397. doi: 10.3390/mi9080397
27. Sun Y, Haglund TA, Rogers AJ, Ghanim AF, Sethu P. Review: microfluidics
technologies for blood-based cancer liquid biopsies. Anal Chim Acta. (2018)
1012:10–29. doi: 10.1016/j.aca.2017.12.050
28. Lima L, Neves M, Oliveira MI, Dieguez L, Freitas R, Azevedo R, et al.
Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal
subtypes facing decreased survival, being expressed by circulating tumor
cells and metastases. Urol Oncol Semin Orig Investig. (2017) 35:675.
doi: 10.1016/j.urolonc.2017.08.012
29. Neves M, Azevedo R, Lima L, Oliveira MI, Peixoto A, Ferreira D, et al.
Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour
cells: a novel biomarker and an analytical tool for precision oncology
applications. New Biotechnol. (2019) 49:77–87. doi: 10.1016/j.nbt.2018.
09.004
30. Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, et al.
Circulating tumor cells as potential biomarkers in bladder cancer. J Urol.
(2015) 194:790–8. doi: 10.1016/j.juro.2015.02.2951
31. Hirai Y, Takagi D, Anai S, Chihara Y, Tsuchiya T, Fujimoto K, et al. ALA-
induced fluorescence detection with photoresist-based microfluidic cell sorter
for bladder cancer diagnosis. Sensors Actuators B Chem. (2015) 213:547–57.
doi: 10.1016/j.snb.2015.01.118
32. Hosseini SA, Zanganeh S, Akbarnejad E, Salehi F, Abdolahad M. Microfluidic
device for label-free quantitation and distinction of bladder cancer cells
from the blood cells using micro machined silicon based electrical approach;
suitable in urinalysis assays. J Pharm Biomed Anal. (2017) 134:36–42.
doi: 10.1016/j.jpba.2016.11.026
33. Chen A, Fu G, Xu Z, Sun Y, Chen X, Cheng KS, et al. Detection of urothelial
bladder carcinoma via microfluidic immunoassay and single-cell DNA copy-
number alteration analysis of captured urinary-exfoliated tumor cells. Cancer
Res. (2018) 78:4073. doi: 10.1158/0008-5472.CAN-17-2615
34. Geng C, Li C, Li W, Yan W, Li J, Aziz AUR, et al. A simple fabricated
microfluidic chip for urine sample-based bladder cancer detection.
J Micromech Microeng. (2018) 28:115011. doi: 10.1088/1361-6439/
aae016
35. Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma MB, Viberti C,
et al. Detection of multiple mutations in urinary exfoliated cells from male
bladder cancer patients at diagnosis and during follow-up. Oncotarget. (2016)
7:67435–48. doi: 10.18632/oncotarget.11883
36. Ferreira JA, Videira PA, Lima L, Pereira S, Silva M, Carrascal M,
et al. Overexpression of tumour-associated carbohydrate antigen
sialyl-Tn in advanced bladder tumours. Mol Oncol. (2013) 7:719–31.
doi: 10.1016/j.molonc.2013.03.001
37. Sullivan PS, Chan JB, Levin MR, Rao J. Urine cytology and adjunct markers
for detection and surveillance of bladder cancer. Am J Transl Res. (2010)
2:412–40.
38. Andersson E, Dahmcke CM, Steven K, Larsen LK, Guldberg P. Filtration
device for on-site collection, storage and shipment of cells from urine and
its application to DNA-based detection of bladder cancer. PLoS ONE. (2015)
10:e0131889. doi: 10.1371/journal.pone.0131889
39. Videira PA, Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, et al.
ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines.
BMC Cancer. (2009) 9:357. doi: 10.1186/1471-2407-9-357
40. Lekka M. Discrimination between normal and cancerous cells using AFM.
BioNanoScience. (2016) 6:65–80. doi: 10.1007/s12668-016-0191-3
41. Rodrigues RO, Pinho D, Faustino V, Lima R. A simple microfluidic device
for the deformability assessment of blood cells in a continuous flow. Biomed.
Microdev. (2015) 17:108. doi: 10.1007/s10544-015-0014-2
42. Kiliçarslan A, Süngü N, Balci S, Canda E, Altinova S, Güler G. The
role of collecting bladder wash fluid before biopsy procedure to help
the cytological diagnosis of residual tumor. J Cytol. (2015) 32:85–9.
doi: 10.4103/0970-9371.160549
43. Keshtkar A, Keshtkar A, Lawford P. Cellular morphological parameters of
the human urinary bladder (malignant and normal). Int J Exp Pathol. (2007)
88:185–90. doi: 10.1111/j.1365-2613.2006.00520.x
Frontiers in Oncology | www.frontiersin.org 12 September 2020 | Volume 10 | Article 1774
Carvalho et al. UriChip for Detection of Bladder Cancer
44. Khandelwal P, Abraham SN, Apodaca G. Cell biology and physiology
of the uroepithelium. Am J Physiol Renal Physiol. (2009) 297:F1477–501.
doi: 10.1152/ajprenal.00327.2009
45. Apodaca G. The uroepithelium: not just a passive barrier. Traffic. (2004)
5:117–28. doi: 10.1046/j.1600-0854.2003.00156.x
46. Bhatia A, Dey P, Kakkar N, Srinivasan R, Nijhawan R. Malignant atypical
cell in urine cytology: a diagnostic dilemma. CytoJournal. (2006) 3:28.
doi: 10.1186/1742-6413-3-28
47. Shojaei-Baghini E, Zheng Y, Jewett MAS, Geddie WB, Sun Y. Mechanical
characterization of benign and malignant urothelial cells from voided urine.
Appl. Phys. Lett. (2013) 102:123704. doi: 10.1063/1.4798495
48. Fogazzi GB, Pallotti F, Garigali G. Atypical/malignant urothelial cells in
routine urinary sediment: worth knowing and reporting. Clin Chim Acta.
(2015) 439:107–11. doi: 10.1016/j.cca.2014.10.021
49. Moll R, Achtstätter T, Becht E, Balcarova-Ständer J, Ittensohn M, Franke
WW. Cytokeratins in normal and malignant transitional epithelium.
Maintenance of expression of urothelial differentiation features in transitional
cell carcinomas and bladder carcinoma cell culture lines. Am J Pathol.
(1988) 132:123–44.
50. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen
ME, et al. Bladder cancer. Nat Rev Dis Primers. (2017) 3:17022.
doi: 10.1038/nrdp.2017.22
51. Wiener HG, Mian CH, Haitel A, Pycha A, Schatzl G, Marberger M. Can
urine bound diagnostic tests replace cystoscopy in the management of bladder
cancer? J Urol. (1998) 159:1876–80. doi: 10.1016/S0022-5347(01)63184-7
52. Keller AK, Jensen JB. Voided urine versus bladder washing cytology for
detection of urothelial carcinoma: which is better? Scand J Urol. (2017)
51:290–2. doi: 10.1080/21681805.2017.1310130
53. Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, et al. Optimization
and evaluation of a novel size based circulating tumor cell isolation system.
PLoS ONE. (2015) 10:e0138032. doi: 10.1371/journal.pone.0138032
54. Renier C, Pao E, Che J, Liu HE, Lemaire CA, Matsumoto M, et al. Label-
free isolation of prostate circulating tumor cells using Vortex microfluidic
technology.NPJ Precision Oncol. (2017) 1:15. doi: 10.1038/s41698-017-0015-0
55. Hou HW, Li QS, Lee GYH, Kumar AP, Ong CN, Lim CT. Deformability study
of breast cancer cells using microfluidics. BiomedMicrodev. (2009) 11:557–64.
doi: 10.1007/s10544-008-9262-8
56. Ramos JR, Pabijan J, Garcia R, Lekka M. The softening of human bladder
cancer cells happens at an early stage of the malignancy process. Beilstein J
Nanotechnol. (2014) 5:447–57. doi: 10.3762/bjnano.5.52
57. Raj A, Sen AK. Entry and passage behavior of biological cells in
a constricted compliant microchannel. RSC Adv. (2018) 8:20884–93.
doi: 10.1039/C8RA02763C
58. Jiang J, Zhao H, Shu W, Tian J, Huang Y, Song Y, et al. An
integrated microfluidic device for rapid and high-sensitivity analysis
of circulating tumor cells. Sci Rep. (2017) 7:42612. doi: 10.1038/
srep42612
59. Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev
Pathol. (2015) 10:473–510. doi: 10.1146/annurev-pathol-012414-040438
60. Munkley J. The role of Sialyl-Tn in cancer. Int J Mol Sci. (2016) 17:275.
doi: 10.3390/ijms17030275
61. Azevedo R, Peixoto A, Gaiteiro C, Fernandes E, Neves M, Lima
L, et al. Over forty years of bladder cancer glycobiology: where do
glycans stand facing precision oncology? Oncotarget. (2017) 8:91734–64.
doi: 10.18632/oncotarget.19433
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Carvalho, Abreu, Ferreira, Lima, Ferreira, Santos, Ribeiro,
Grenha, Martínez-Fernández, Duenas, Suárez-Cabrera, Paramio, Diéguez, Freitas
andOliveira. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org 13 September 2020 | Volume 10 | Article 1774
